Table 1.
Demographics of immunocompromised pediatric patients who received T-C.
| Variables | n=24 | |
|---|---|---|
| Age (median [range]) | 16.50 [12 – 21] | |
| Gender (%) | Female | 14 (58.3) |
| Male | 10 (41.7) | |
| Race (%) | Black or African American | 7 (29.2) |
| Other | 2 (8.3) | |
| White | 15 (62.5) | |
| Ethnicity (%) | Hispanic | 7 (29.2) |
| Not Hispanic | 17 (70.8) | |
| Diagnosis (%) | Mixed phenotype leukemia | 1 (4.2) |
| ALL | 6 (25.0) | |
| AML | 7 (29.2) | |
| Hematologic Disease | 10 (41.7) | |
| Reason to receive T-C | < 100 days from allogenic HCT Graft versus host disease Post CAR-T therapy Chemotherapy Other* |
13 (54.2) 4 (16.7) 3 (12.5) 2 (8.3) 2 (8.3) |
| SARS-CoV-2 Vaccination Received | ||
| Pfizer-BioNTech (%) | No | 4 (16.7) |
| Yes | 20 (83.3) | |
| Moderna (%) | No | 15 (62.5) |
| Yes | 9 (37.5) | |
| Janssen (%) | No | 20 (83.3) |
| Yes | 4 (16.7) | |
| Received > 2 doses of vaccine (%) | No | 7 (29.2) |
| Yes | 17 (70.8) | |
| Number of vaccine doses/patient before T-C (median [range]) | 2 [0 – 3] | |
| SARS-CoV-2 infection before T-C dose infection, no. (%) | No | 22 (91.7) |
| Yes | 2 (8.3) | |
| Time between SARS-CoV-2 infection and first dose T-C (median [range]) | 63.50 [6–121] | |
| Platelet count prior to any T-C dose (median [range] 103/ mm3) | 170 [25-561] | |
| SARS-CoV-2 infection <=180 days from any T-C dose | No | 17 (70.8) |
| Yes | 7 (29.2) | |
| Time between any dose T-C and SARS-CoV-2 infection (median [range]) | 102 [28–135] | |
*Other: Lupus on immunosuppressive therapy (n=1); Kidney transplant recipient on immunosuppressive therapy ^ Hematologic diseases: Aplastic Anemia (n=4), Sickle Cell Disease (n=4), Acquired Factor II deficiency (n=1), Myelodysplastic Syndrome (n=1).